Medical News and Perspectives
March 6, 2013

FDA Warning: New Batch of Fake Bevacizumab Found

JAMA. 2013;309(9):864. doi:10.1001/jama.2013.1719

A counterfeit version of the injectable cancer drug bevacizumab that may contain no active ingredient has been distributed to clinics in the United States, according to a US Food and Drug Administration (FDA) alert to physicians. The incident is the latest in a string of cases in which foreign drug distributors have sold counterfeit medications to US medical practices.

According to the warning (, a US company calling itself Medical Device King (also known as Pharmalogical) distributed 2 batches of a counterfeit version of bevacizumab labeled as Altuzan. The counterfeits were labeled as Altuzan, 400 mg/16 mL, and had batch numbers B6022B01 (which bear an expiration date of November 2013) and B6024B01 (with an expiration date of February 2013).

First Page Preview View Large
First page PDF preview
First page PDF preview